FeesSafety
Pluang+

DTE Energy offers strong dividend growth and 24% upside potential by 2027 amid Michigan data center boom.

Analyst Insights
25 Sep 2026, 15:00 WIB
Seeking Alpha
View Source
Bullish
DTE Energy offers strong dividend growth and 24% upside potential by 2027 amid Michigan data center boom.

DTE Energy is positioned for 6–8% annual earnings growth through 2030, supported by a $36.5 billion capital plan linked to major deals with Oracle and Google in Michigan's expanding data center market. The stock trades at a forward P/E of 16.36, below its fair value multiple of 18, indicating a potential 24% price increase by 2027 and 12% annual returns through 2031. With a 3.4% dividend yield and a low payout ratio, DTE balances growth and affordability despite risks from rising interest rates and regulatory challenges. This makes it an attractive option for investors seeking income and capital gains.

DTE Energy's outlook for dividend growth and earnings is presented here alongside Pluang's Utilities-sector market snapshot as of Sep 25, 2026 19:12 WIB: Of 22 priced US Utilities stocks on Pluang, 14 rose and 7 fell. Notable prices include Xcel Energy Inc (XEL) at USD 69.76 with a 0.29% increase, AES Corp (AES) at USD 14.88 with a 0.20% increase and 100% buy order activity, and Consolidated Edison, Inc. (ED) at USD 102.52 with a 0.18% decrease. Typical hold times range from 60 to 74 days among these stocks.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
20 minutes ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
20 minutes ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
1 hour ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
1 hour ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App